[HTML][HTML] Targeting immune checkpoints in hematological malignancies
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
[HTML][HTML] Targeting immune checkpoints in hematological malignancies
B Salik, MJ Smyth, K Nakamura - Journal of Hematology & …, 2020 - ncbi.nlm.nih.gov
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
Targeting immune checkpoints in hematological malignancies
B Salik, MJ Smyth, K Nakamura - Journal of Hematology & …, 2020 - search.proquest.com
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
[PDF][PDF] Targeting immune checkpoints in hematological malignancies
B Salik, MJ Smyth, K Nakamura - 2020 - scholar.archive.org
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
Targeting immune checkpoints in hematological malignancies.
B Salik, MJ Smyth, K Nakamura - Journal of Hematology & …, 2020 - search.ebscohost.com
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
[HTML][HTML] Targeting immune checkpoints in hematological malignancies
B Salik, MJ Smyth, K Nakamura - … of Hematology & …, 2020 - jhoonline.biomedcentral.com
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
Targeting immune checkpoints in hematological malignancies.
B Salik, MJ Smyth, K Nakamura - Journal of Hematology & Oncology, 2020 - go.gale.com
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
[引用][C] Targeting immune checkpoints in hematological malignancies
B Salik, MJ Smyth, K Nakamura - Journal of Hematology …, 2020 - espace.library.uq.edu.au
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
Targeting immune checkpoints in hematological malignancies
B Salik, MJ Smyth, K Nakamura - Journal of hematology …, 2020 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
Targeting immune checkpoints in hematological malignancies.
B Salik, MJ Smyth, K Nakamura - Journal of Hematology & Oncology, 2020 - europepmc.org
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …